IMD-101 is under clinical development by Shanghai Affinity Biopharmaceutical and currently in Phase I for Bladder Cancer. According to GlobalData, Phase I drugs for Bladder Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IMD-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMD-101 overview
IMD-101 is under development for the treatment of solid tumor, melanoma, non-small cell lung cancer (NSCLC), renal cell cancer, mesothelioma and bladder cancer. The therapeutic candidate is an interleukin 2 conjugate. It is being developed based on TMEA platform. It is administered through intravenous route.
Shanghai Affinity Biopharmaceutical overview
Shanghai Affinity Biopharmaceutical (Affinity Biopharma) is a clinical-stage biopharmaceutical company. The company develops tumor microenvironment-activated (TMEA) intelligent platforms for small-molecule drugs and biologics. It offers an oral antibacterial bio gel product, Gelsooth, for oral protection and antibacterial care. Affinity Biopharma’s TMEA platform technology includes TMEA small molecule drug conjugates, TMEA cytokine, TMEA antibody, TMEA antibody-drug conjugates, TMEA fusion cytokine, and TMEA immune cell engager. The company is developing a broad range of products pipeline in the areas of precision-guided chemotherapy, precision-guided target therapy, and biologics conjugates for cancer treatments. Affinity Biopharma is headquartered in Shanghai, China.
For a complete picture of IMD-101’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
